Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-03-08
1998-05-12
Ulm, John
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514866, 530304, C07K 1462, A61K 3828
Patent
active
057504970
ABSTRACT:
The present invention relates to human insulin derivatives having a protracted profile of action in which the A21 and B3 amino acid residues are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; Phe.sup.B1 may be deleted; the B30 amino acid residue is (a) a non-codable, lipophilic amino acid having from 10 to 24 carbon atoms in which case an acyl group of a carboxylic acid with up to 5 carbon atoms is bound to the E-amino group of Lys.sup.B29 ; (b) any amino acid residue which can be coded by the genetic code except Lys, Arg and Cys, in which case a lipophilic substituent is bound to the E-amino group of Lys.sup.B29 ; or (c) deleted, in which case a lipophilic substituent is bound to the E-amino group of LyS.sup.B29 ; and any Zn.sup.2+ complexes thereof; provided that when the B30 amino acid residue is Thr or Ala, the A21 and B3 amino acid residues are both Asn and Phe.sup.B1 is present, then the insulin derivative is a Zn.sup.2 + complex.
REFERENCES:
patent: 3823125 (1974-07-01), Grant et al.
patent: 3868356 (1975-02-01), Smyth
patent: 3950517 (1976-04-01), Lindsay et al.
patent: 4645740 (1987-02-01), Breddam et al.
patent: 5008241 (1991-04-01), Markussen et al.
Brange J., Galenics of Insulin, pp.18-100 (1987).
Blundell T. et al., The Structure in the Crystal and its Reflection in Chemistry and Biology, vol. 26, pp.279-402 (1972).
Hashimoto, et al., Pharmaceutical Research, vol. 6, No. 2, pp. 171-176 (1989).
Muranishi et al., Journal of Controlled Release, vol. 19, pp. 179-188 (1992).
Brunfeldt, ACTA Endocrinol. 61: 561-576, 1969.
Markussen, Prot. Eng. 2:157-166, 1988.
Markussen, Prot. Eng. 1:205-213, 1987.
GammeHoft, Phys. Rev 64: 1321-1378, 1984.
Andersen Asser Sloth
Halstr.o slashed.m John
Havelund Svend
Jonassen Ib
Markussen Jan
Lambiris Elias J.
Novo Nordisk A S
Saoud Christine
Ulm John
Zelson Steve T.
LandOfFree
Acylated insulin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Acylated insulin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acylated insulin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-979080